Research programme: neoepitope-based immunotherapies - Advaxis

Drug Profile

Research programme: neoepitope-based immunotherapies - Advaxis

Alternative Names: ADXS NEO

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advaxis; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Sep 2017 Advaxis plans a phase I trial for Cancer in the first half of 2018
  • 06 Mar 2017 US FDA accepts IND application for ADXS NEO in Cancer
  • 09 Jan 2017 Advaxis announces intention to submit IND to US FDA in early 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top